Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 6Neoplasms 3Neoplasm Metastasis 3Recurrence 2Melanoma 2Lymphoma, B-Cell, Marginal Zone 2Head and Neck Neoplasms 2Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Nephrotic Syndrome 1Myeloproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Locally Advanced Bladder Cancer 1Leukemia, Lymphocytic, Chronic, B-Cell 1Kidney Diseases 1Hepatitis B 1Gastrointestinal Diseases 1Familial Mediterranean Fever 1Esophageal Neoplasms 1Depression 1Carcinoma, Squamous Cell 1Breast Neoplasms 1Brain Neoplasms 1Arthritis, Rheumatoid 1Anxiety Disorders 1

Interventions

Oxaliplatin 4Fluorouracil 4Magnetic Resonance Spectroscopy 35,10-methylenetetrahydrofolic acid 3Ocoxin 2Leucovorin 2Irinotecan 2Cyclophosphamide 2Bevacizumab 2trifluridine tipiracil drug combination 1sintilimab 1pralsetinib 1pembrolizumab 1napabucasin 1huachansu 1guadecitabine 1Ursodeoxycholic Acid 1Surveys and Questionnaires 1S-1 plus cisplatin 1Pharmaceutical Preparations 1Pemetrexed 1Paclitaxel 1Oviposition 1Levoleucovorin 1Infliximab 1Imatinib Mesylate 1Gemcitabine 1Exercise Test 1Drainage 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Gastrointestinal Diseases × Pharmaceutical Preparations × Clear all
NCT00035334 2006-02-14

Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis

Bellus Health Inc. - a GSK company

Phase 2/3 Completed
150 enrolled
GastrointestinalGenitourinaryPlasma cell

Amyloidosis, Arthritis, Rheumatoid, Gastrointestinal Diseases, Kidney Diseases, Neoplasm Metastasis, Nephrotic Syndrome, Familial Mediterranean Fever

Data powered by HemOnc (CC BY 4.0) Colophon âš¡